The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus
Abstract
Severe systemic lupus erythematosus affecting the kidney or central nervous system may lead to organ failure or death despite treatment with high doses of corticosteroids. To evaluate the clinical and immunologic effects of intravenous cyclophosphamide in this setting, we treated nine patients with monthly intravenous infusions of cyclophosphamide for six months. A comparison of characteristics at entry and follow-up revealed improvements (by paired t-test) in creatinine clearance (66 vs. 96 ml per minute, P less than 0.001); 24-hour urinary protein level (4.11 vs. 0.90 g, P less than 0.05), Farr anti-DNA titer (43 vs. 8.5 percent, P less than 0.01); complement components C3 (894 vs. 1150 mg per liter, P less than 0.05), C4 (154 vs. 222 mg per liter, P less than 0.05), and total complement activity (CH50) (88.7 vs. 113.4 IU, P less than 0.05); and Westergren erythrocyte sedimentation rate (60.2 vs. 34.4 mm per hour, P less than 0.0005). Other manifestations of lupus improved markedly in most cases, despite a reduction in the mean daily dose of prednisone, from 45 mg at entry to 17 mg at follow-up (P less than 0.01). The numbers of lymphocytes positive for T3, T4, T8, and B1 declined progressively during treatment. At follow-up, persistent decreases were observed in the T-lymphocyte subsets, whereas the absolute number of B lymphocytes had returned to levels near base line. T-cell proliferative responses at follow-up were not significantly different from entry values, except that the response to mitogenic anti-T11 (CD2) antibodies was decreased (P less than 0.01). Our data indicate that monthly intravenous administration of cyclophosphamide was associated with a substantial amelioration of severe systemic lupus, in conjunction with discrete changes in T-lymphocyte markers and T-cell function. This was a preliminary, uncontrolled study, but the results warrant further investigation of this form of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Meuer, S. C., Hussey, R. E., Fabbi, M., Fox, D., Acuto, O., Fitzgerald, K. A., Hodgdon, J. C., Protentis, J. P., Schlossman, S. F., & Reinherz, E. L. (1984) · Cell · doi:10.1016/0092-8674(84)90039-4 · Cited by 1,113
Self-citationCharacterization of a human B lymphocyte-specific antigen.
Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076
Prognostic factors in lupus nephritis
Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T., Kullick, M. E., Klippel, J. H., Decker, J. L., & Balow, J. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90338-8 · Cited by 773
An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2
Seed, B. (1987) · Nature · doi:10.1038/329840a0 · Cited by 681
Cyclophosphamide cystitis—Identification of acrolein as the causative agent
Cox, P. J. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90222-3 · Cited by 572
Meuer, S. C., Hussey, R. E., Cantrell, D. A., Hodgdon, J. C., Schlossman, S. F., Smith, K. A., & Reinherz, E. L. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1509 · Cited by 495
The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3
Selvaraj, P., Plunkett, M. L., Dustin, M., Sanders, M. E., Shaw, S., & Springer, T. A. (1987) · Nature · doi:10.1038/326400a0 · Cited by 442
Measurement of Serum DNA-Binding Activity in Systemic Lupus Erythematosus
Pincus, T., Schur, P. H., Rose, J. A., Decker, J. L., & Talal, N. (1969) · New England Journal of Medicine · doi:10.1056/nejm196909252811304 · Cited by 441
Cited by
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Paraquat Poisonings: Mechanisms of Lung Toxicity, Clinical Features, and Treatment
Dinis-Oliveira, R. J., Duarte, J. A., Sánchez-Navarro, A., Remião, F., Bastos, M. L., & Carvalho, F. (2008) · Critical Reviews in Toxicology · doi:10.1080/10408440701669959 · Cited by 926
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Metadata
- Authors
- McCune, W. J., Golbus, J., Zeldes, W., Bohlke, P., Dunne, R., & Fox, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1988-06-02
- Volume
- 318
- Issue
- 22
- Pages
- 1423-1431
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336821934
- Cited by
- 282
- References
- 31
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus. https://app.cochat.ai/papers/10.1056/nejm198806023182203
- The paper
- McCune, W. J., Golbus, J., Zeldes, W., Bohlke, P., Dunne, R., & Fox, D. A. (1988). Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus. New England Journal of Medicine. https://doi.org/10.1056/nejm198806023182203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.